FDA Application for Orphan Drug Designation , PAA, MPL, page-338

Big Pharma has a huge appetite to identify and acquire novel treatments .

I remain convinced that Monepantel has intrinsic value which is calculated in the billions. The key question for PAA is how to realise maximum value in bringing our product to a commercial outcome.

Riluzole, the current standard of care for MND has $1bn+ annual sales. With a long patent runway and superior clinical results I expect Monepantel to figure highly on Big Pharma's radar.

Back in May we received the research paper from Prof Fairlie which looked at the anti-tumor activity of Monepantel across multiple human cancer types. It was heavy duty research many years in the making. The implications are mind-blowing.

For anyone who has not viewed the research paper:

https://onlinelibrary.wiley.com/doi/10.1002/cam4.6021

My feeling is that PAA will be targeting Phase 2 Human Cancer clinical trials as soon as finances permit. It has always been the ultimate objective. If a BP want to buy us out early, then I reckon the valuation of Monepantel as a combination therapy for multiple human cancers should be foremost in discussions.

PAA may be a minnow regarding our share price, but we have something of immense value. It may be a little while down the road, but I think we may be setting a new high benchmark in BioTech deals.

My opinion only, Cheers, Thrifty